Lord Abbett Health Care Fund Class I (LHCIX)
| Fund Assets | 3.27M |
| Expense Ratio | 0.78% |
| Min. Investment | $1,000,000 |
| Turnover | n/a |
| Dividend (ttm) | 0.11 |
| Dividend Yield | 0.61% |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | Nov 26, 2024 |
| Previous Close | 17.90 |
| YTD Return | -7.13% |
| 1-Year Return | -5.12% |
| 5-Year Return | 26.27% |
| 52-Week Low | 16.71 |
| 52-Week High | 21.07 |
| Beta (5Y) | n/a |
| Holdings | 66 |
| Inception Date | Jul 31, 2019 |
About LHCIX
The Fund's investment strategy focuses on Health/Biotech with 0.78% total expense ratio. The minimum amount to invest in Lord Abbett Securities Trust: Lord Abbett Health Care Fund; Class I Shares is $1,000,000 on a standard taxable account. Lord Abbett Securities Trust: Lord Abbett Health Care Fund; Class I Shares seeks long-term capital appreciation. Under normal market conditions, LHCIX will invest at least 80% of its assets in equity and equity-related securities of health care-related companies. LHCIX may invest in the securities of issuers of different countries throughout the world, including the United States.
Performance
LHCIX had a total return of -5.12% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.76%.
Top 10 Holdings
40.46% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 8.74% |
| Boston Scientific Corporation | BSX | 4.92% |
| Intuitive Surgical, Inc. | ISRG | 4.78% |
| Gilead Sciences, Inc. | GILD | 3.94% |
| Stryker Corporation | SYK | 3.74% |
| argenx SE | ARGX | 3.56% |
| Natera, Inc. | NTRA | 3.06% |
| Tarsus Pharmaceuticals, Inc. | TARS | 2.94% |
| Cencora, Inc. | COR | 2.61% |
| UCB SA | UCB | 2.14% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Nov 26, 2024 | $0.1098 | Nov 26, 2024 |
| Nov 22, 2022 | $0.0239 | Nov 22, 2022 |
| Nov 23, 2021 | $1.4724 | Nov 23, 2021 |
| Nov 24, 2020 | $2.3119 | Nov 24, 2020 |
| Nov 21, 2019 | $0.0073 | Nov 21, 2019 |